Compare Fresenius Kabi Onco. with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs STRIDES PHARMA SCIENCE - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. STRIDES PHARMA SCIENCE FRESENIUS KABI ONCO./
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 22.1 14.2 155.9% View Chart
P/BV x 3.1 0.8 371.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
STRIDES PHARMA SCIENCE
Mar-18
FRESENIUS KABI ONCO./
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1761,147 15.3%   
Low Rs79642 12.2%   
Sales per share (Unadj.) Rs37.7317.2 11.9%  
Earnings per share (Unadj.) Rs5.17.8 64.9%  
Cash flow per share (Unadj.) Rs6.725.1 26.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs42.5274.3 15.5%  
Shares outstanding (eoy) m158.2389.50 176.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.8 119.8%   
Avg P/E ratio x25.0114.0 21.9%  
P/CF ratio (eoy) x18.935.7 53.0%  
Price / Book Value ratio x3.03.3 91.7%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m20,13580,058 25.2%   
No. of employees `0001.22.5 46.0%   
Total wages/salary Rs m7034,341 16.2%   
Avg. sales/employee Rs Th5,176.211,325.8 45.7%   
Avg. wages/employee Rs Th610.41,731.4 35.3%   
Avg. net profit/employee Rs Th699.6280.1 249.8%   
INCOME DATA
Net Sales Rs m5,96328,394 21.0%  
Other income Rs m18941 1.9%   
Total revenues Rs m5,98129,334 20.4%   
Gross profit Rs m1,4303,965 36.1%  
Depreciation Rs m2581,540 16.7%   
Interest Rs m-261,962 -1.3%   
Profit before tax Rs m1,2161,403 86.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-68-436 15.6%   
Tax Rs m34297 351.7%   
Profit after tax Rs m806702 114.8%  
Gross profit margin %24.014.0 171.7%  
Effective tax rate %28.16.9 405.8%   
Net profit margin %13.52.5 546.6%  
BALANCE SHEET DATA
Current assets Rs m5,10224,836 20.5%   
Current liabilities Rs m2,38518,993 12.6%   
Net working cap to sales %45.620.6 221.4%  
Current ratio x2.11.3 163.6%  
Inventory Days Days15071 211.4%  
Debtors Days Days113113 99.9%  
Net fixed assets Rs m5,14834,289 15.0%   
Share capital Rs m158895 17.7%   
"Free" reserves Rs m6,55623,651 27.7%   
Net worth Rs m6,73224,546 27.4%   
Long term debt Rs m95215,513 6.1%   
Total assets Rs m10,38865,437 15.9%  
Interest coverage x-45.81.7 -2,669.1%   
Debt to equity ratio x0.10.6 22.4%  
Sales to assets ratio x0.60.4 132.3%   
Return on assets %7.54.1 184.4%  
Return on equity %12.02.9 418.5%  
Return on capital %14.66.9 211.8%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29815,697 33.7%   
Fx outflow Rs m1,772735 241.0%   
Net fx Rs m3,52514,962 23.6%   
CASH FLOW
From Operations Rs m1,2741,871 68.1%  
From Investments Rs m-1,2045,826 -20.7%  
From Financial Activity Rs m-196-10,157 1.9%  
Net Cashflow Rs m-126-2,615 4.8%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 37.8 0.8%  
FIIs % 9.6 8.6 111.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.9 35.1%  
Shareholders   42,599 56,241 75.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PLETHICO PHARMA  AJANTA PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; HCL Technologies & SBI Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS